Assessment of Long-Term Health Effects of Antimalarial Drugs When Used for Prophylaxis (2020) / Chapter Skim
Currently Skimming:
Appendix C: Epidemiologic Studies That Met the Committee's Inclusion Criteria
Appendix C: Epidemiologic Studies That Met the Committee's Inclusion Criteria
Pages 393-398
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 393... ...
Appendix C Epidemiologic Studies That Met the Committee's Inclusion Criteria 393
|
From page 394... ...
Placebo (n = 60) DeSouza, 1983 Clinical trial Healthy male adult volunteers (age Mefloquine Gastrointestinal range not reported)
|
From page 395... ...
recruited Placebo (n = 39) Other from the United States and the United Kingdom Lee et al., 2013 Cross-sectional survey Current and former male and Doxycycline (n = 189)
|
From page 396... ...
Psychiatric study Schneider et al., Retrospective Male and female travelers (ages Mefloquine (n = 10,169) Neurologic 2013*
|
From page 397... ...
Primaquine (n = 106) 15 mg daily for individuals with a body weight of <70 kg 30 mg daily for individuals with a body weight of >70 kg Hydroxychloroquine (200 mg)
|
From page 398... ...
† Although study investigators did not make a traditional comparison between exposed and unexposed groups, they did compare individuals who experienced adverse events with those who did not experience adverse events in the data analysis; thus, the committee included this study in their evaluation of the available scientific evidence. ‡ For the six antimalarial drugs of interest the dosing regimen used follows standard FDA guidance unless otherwise noted.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.